Interpretation and use of natriuretic peptides in non-congestive heart failure settings

Yonsei Medical Journal

Volumn 51, Issue 2, 2010, Pages 151-163

  Tsai, Shih Hung ^a   Lin, Yen Yue ^a   Chu, Shi Jye ^a   Hsu, Ching Wang ^a   Cheng, Shu Meng ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Acute coronary syndrome; Carbon monoxide intoxication; Cardiac dysrhythmia; Cirrhosis of liver; Hyperthyroidism; Natriuretic peptides; Pulmonary embolism; Pulmonary hypertension; Renal failure; Sepsis; Stroke

Indexed keywords

ANTIARRHYTHMIC AGENT; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; FIBRINOLYTIC AGENT; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDE RECEPTOR B; NATRIURETIC PEPTIDE TYPE C; PACLITAXEL;

ACUTE CORONARY SYNDROME; ACUTE ISCHEMIC STROKE; AORTA DISSECTION; AORTA VALVE STENOSIS; BACTERIAL ENDOCARDITIS; CARBON MONOXIDE INTOXICATION; CARDIOGENIC SYNCOPE; CEREBROVASCULAR ACCIDENT; CHRONIC LUNG DISEASE; COMORBIDITY; CONGENITAL HEART DISEASE; CRITICAL ILLNESS; DYSPNEA; EPILEPSY; EXTRACORPOREAL OXYGENATION; FIBRINOLYTIC THERAPY; HEART AMYLOIDOSIS; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE FUNCTION; HEART SURGERY; HEART TRANSPLANTATION; HEART VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPERTHYROIDISM; KIDNEY FAILURE; LIVER CIRRHOSIS; LUNG EMBOLISM; MITRAL VALVE DISEASE; MORBID OBESITY; MYOCARDITIS; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PROGNOSIS; PULMONARY HYPERTENSION; RESPIRATORY FAILURE; REVIEW; RHEUMATIC FEVER; SCREENING; SEPSIS; SHOCK; SLEEP APNEA SYNDROME; SUBARACHNOID HEMORRHAGE; THERAPY EFFECT;

ACUTE CORONARY SYNDROME; ARRHYTHMIAS, CARDIAC; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; NATRIURETIC PEPTIDES; SEPSIS;

EID: 77649195703     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2010.51.2.151     Document Type: Review

References (112)

1. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.
2. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 2006;27:330-7.
3. Kisch B. Electron microscopy of the atrium of the heart. I. Guinea pig. Exp Med Surg 1956;14:99-112.
4. De Bold AJ. Heart atria granularity effects of changes in waterelectrolyte balance. Proc Soc Exp Biol Med 1979;161:508-11.
5. Iwanaga Y, Nishi I, Furuichi S, Noguchi T, Sase K, Kihara Y, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 2006;47:742-8.
6. Burjonroppa SC, Tong AT, Xiao LC, Johnson MM, Yusuf SW, Lenihan DJ. Cancer patients with markedly elevated B-type natriuretic peptide may not have volume overload. Am J Clin Oncol 2007;30:287-93.
7. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-85.
8. Young JB, Correia NG, Francis GS, Maisel A, Michota F.Testing for B-type natriuretic peptide in the diagnosis and assessment of heart failure: what are the nuances? Cleve Clin J Med 2004;71 Suppl 5:S1-17.
9. Hawkridge AM, Heublein DM, Bergen HR 3rd, Cataliotti A, Burnett JC Jr, Muddiman DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U SA 2005;102:17442-7.
10. Omland T. Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure. Crit Care Med 2008;36:S17-27.
11. Prontera C, Zaninotto M, Giovannini S, Zucchelli GC, Pilo A, Sciacovelli L, et al. Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: the CardioOrmocheck study. Clin Chem Lab Med 2009. In press.
12. Chen AA, Wood MJ, Krauser DG, Baggish AL, Tung R, Anwaruddin S, et al. NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur Heart J 2006;27:839-45.
13. Vanderheyden M, Bartunek, Claeys G, Manoharan G, Beckers JF, Ide L. Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction. Clin Biochem 2006;39:640-5.
14. Brown A, George J, Murphy MJ, Struthers A. Could BNP screening of acute chest pain cases lead to safe earlier discharge of patients with non-cardiac causes? A pilot study. QJM 2007;100:755-61.
15. Fukuta H, Ohte N, Mukai S, Saeki T, Kobayashi K, Kimura G. Anemia is an independent predictor for elevated plasma levels of natriuretic peptides in patients undergoing cardiac catheterization for coronary artery disease. Circ J 2008;72:212-7.
16. Ogawa A, Seino Y, Yamashita T, Ogata K, Takano T. Difference in elevation of N-terminal pro-BNP and conventional cardiac markers between patients with ST elevation vs non-ST elevation acute coronary syndrome. Circ J 2006;70:1372-8.
17. Sinclair H, Paterson M, Walker S, Beckett G, Fox KA. Predicting outcome in patients with acute coronary syndrome: evaluation of B-type natriuretic peptide and the global registry of acute coronary events (GRACE) risk score. Scott Med J 2007;52:8-13.
18. Günes Y, Okçün B, Kavlak E, Erbas C, Karcier S. Value of brain natriuretic peptide after acute myocardial infarction. Anadolu Kardiyol Derg 2008;8:182-7.
19. Kwan G, Isakson SR, Beede J, Clopton P, Maisel AS, Fitzgerald RL. Short-term serial sampling of natriuretic peptides in patients presenting with chest pain. J Am Coll Cardiol 2007;49:1186-92.
20. Palazzuoli A, Rizzello V, Calabrò A, Gallotta M, Martini G, Quatrini I, et al. Osteoprotegerin and B-type natriuretic peptide in non-ST elevation acute coronary syndromes: relation to coronary artery narrowing and plaques number. Clin Chim Acta 2008;391:74-9.
21. Sun T, Wang L, Zhang Y. Prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. Arch Med Res 2006;37:502-5.
22. Fonarow GC, Peacock WF, Horwich TB, Phillips CO, Givertz MM, Lopatin M, et al. Usefulness of B-Type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. Am J Cardiol 2008;101:231-7.
23. Tello-Montoliu A, Marín F, Roldán V, Mainar L, López MT, Sogorb F, et al. A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels. J Intern Med 2007;262:651-8.
24. Morrow DA, de Lemos JA, Blazing MA, Sabatine MS, Murphy SA, Jarolim P, et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA 2005;294:2866-71.
25. Yildirir A, Acikel S, Ertan C, Aydinalp A, Ozin B, Muderrisoglu H. Value of peri-procedural B-type natriuretic peptide levels in predicting cardiac events after elective percutaneous coronary intervention. Acta Cardiol 2008;63:47-52.
26. Lo Mauro R, Arcoleo F, Lo Giudice A, Picone A, Schirosa M, Raspanti G, et al. B-type natriuretic peptide as a marker of asymptomatic re-stenosis after coronary implantation of a paclitaxeleluting stent. J Cardiovasc Med (Hagerstown) 2007;8:1020-3.
27. Elíasdóttir SB, Klemenzson G, Torfason B, Valsson F. Brain natriuretic peptide is a good predictor for outcome in cardiac surgery. Acta Anaesthesiol Scand 2008;52:182-7.
28. Turk T, Ata Y, Ay D, Ozkan H, Vural H, Yavuz S, et al. Plasma brain natriuretic peptide after isolated on-pump coronary artery bypass grafting: prediction of postoperative adverse outcomes. Heart Surg Forum 2008;11:E84-9.
29. Sarzi Braga S, Vaninetti R, Pedretti RF. Plasma B-type natriuretic peptide predicts atrial fibrillation during rehabilitation after cardiac surgery. Eur J Cardiovasc Prev Rehabil 2008;15:460-6.
30. Shaw SM, Fildes J, Yonan N, Williams SG. Does brain natriuretic peptide interact with the immune system after cardiac transplantation? Transplantation 2007;84:1377-81.
31. Rossano JW, Denfield SW, Kim JJ, Price JF, Jefferies JL, Decker JA, et al. B-type Natriuretic peptide is a sensitive screening test for acute rejection in pediatric heart transplant patients. J Heart Lung Transplant 2008;27:649-54.
32. Martínez-Dolz L, Almenar L, Hervás I, Moro J, Agüero J, Sánchez-Lázaro I, et al. Prognostic relationship between two serial determinations of B-type natriuretic peptide and mediumlong-term events in heart transplantation. J Heart Lung Transplant 2008;27:735-40.
33. Heise G, Lemmer J, Weng Y, Hübler M, Alexi-Meskishvili V, Böttcher W, et al. Biomarker responses during mid-term mechanical cardiac support in children. J Heart Lung Transplant 2008;27:150-7.
34. Pruszczyk P. N-terminal pro-brain natriuretic peptide as an indicator of right ventricular dysfunction. J Card Fail 2005;11:S65-9.
35. Alonso-Martínez JL, Urbieta-Echezarreta M, Anniccherico- Sánchez FJ, Abínzano-Guillén ML, Garcia-Sanchotena JL. Nterminal pro-B-type natriuretic peptide predicts the burden of pulmonary embolism. Am J Med Sci 2009;337:88-92.
36. Yardan T, Altintop L, Baydin A, Yilmaz O, Guven H. B-type natriuretic peptide as an indicator of right ventricular dysfunction in acute pulmonary embolism. Int J Clin Pract 2008;62:1177-82.
37. Binder L, Pieske B, Olschewski M, Geibel A, Klostermann B, Reiner C, et al. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation 2005;112:1573-9.
38. Enea I, Ceparano G, Mazzarella G, Di Sarno R, Cangiano G, Busino CA. [Biohumoral markers and right ventricular dysfunction in acute pulmonary embolism: the answer to thrombolytic therapy.] Ital Heart J Suppl 2004;5:29-35.
39. Logeart D, Lecuyer L, Thabut G, Tabet JY, Tartière JM, Chavelas C, et al. Biomarker-based strategy for screening right ventricular dysfunction in patients with non-massive pulmonary embolism. Intensive Care Med 2007;33:286-92.
40. Yap LB, Mukerjee D, Timms PM, Ashrafian H, Coghlan JG. Natriuretic peptides, respiratory disease, and the right heart. Chest 2004;126:1330-6.
41. Yano S, Kobayashi K, Kato K, Ikeda T. [The study of pulmonary hypertension and plasma BNP values in respiratory diseases.] Nihon Kokyuki Gakkai Zasshi 2006;44:99-103.
42. Andreassen AK, Wergeland R, Simonsen S, Geiran O, Guevara C, Ueland T. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 2006;98:525-9.
43. Yap LB, Mukerjee D, Timms PM, Ashrafian H, Coghlan JG. Natriuretic peptides, respiratory disease, and the right heart. Chest 2004;126:1330-6.
44. Kanat F, Vatansev H, Teke T. Diuretics, plasma brain natriuretic peptide and chronic obstructive pulmonary disease. Neth J Med 2007;65:296-300.
45. Stolz D, Breidthardt T, Christ-Crain M, Bingisser R, Miedinger D, Leuppi J, et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 2008;133:1088-94.
46. Chien JY, Lin MS, Huang YC, Chien YF, Yu CJ, Yang PC. Changes in B-type natriuretic peptide improve weaning outcome predicted by spontaneous breathing trial. Crit Care Med 2008;36:1421-6.
47. Moe GW, Howlett J, Januzzi JL, Zowall H; Canadian Multicenter Improved Management of Patients With Congestive Heart Failure (IMPROVE-CHF) Study Investigators. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007;115:3103-10.
48. Iltumur K, Karabulut A, Yokus B, Yavuzkir M, Taskesen T, Toprak N. N-terminal proBNP plasma levels correlate with severity of mitral stenosis. J Heart Valve Dis 2005;14:735-41.
49. Arat-Ozkan A, Kaya A, Yigit Z, Balci H, Okçün B, Yazicioglu N, et al. Serum N-terminal pro-BNP levels correlate with symptoms and echocardiographic findings in patients with mitral stenosis. Echocardiography 2005;22:473-8.
50. Cemri M, Arslan U, Kocaman SA, Cengel A. Relationship between N-terminal pro-B type natriuretic peptide and extensive echocardiographic parameters in mild to moderate aortic stenosis. J Postgrad Med 2008;54:12-6.
51. Della Corte A, Salerno G, Chiosi E, Iarussi D, Santarpino G, Miraglia M, et al. Preoperative, postoperative and 1-year follow-up N-terminal pro-B-type natriuretic peptide levels in severe chronic aortic regurgitation: correlations with echocardiographic findings. Interact Cardiovasc Thorac Surg 2008;7:419-24.
52. Moura LM, Rocha-Gonçalves F, Zamorano JL, Barros I, Bettencourt P, Rajamannan N. New cardiovascular biomarkers: clinical implications in patients with valvular heart disease. Expert Rev Cardiovasc Ther 2008;6:945-54.
53. Iversen K, Nielsen OW, Kirk V, Bay M, Hassager C, Boesgaard S, et al. Heart murmur and N-terminal pro-brain natriuretic peptide as predictors of death in 2977 consecutive hospitalized patients. Am J Med Sci 2008;335:444-50.
54. Therkelsen SK, Groenning BA, Kjaer A, Svendsen JH, Boje Jensen G. ANP and BNP in atrial fibrillation before and after cardioversion - and their relationship to cardiac volume and function. Int J Cardiol 2008;127:396-9.
55. Sacher F, Corcuff JB, Schraub P, Le Bouffos V, Georges A, Jones SO, et al. Chronic atrial fibrillation ablation impact on endocrine and mechanical cardiac functions. Eur Heart J 2008;29:1290-5.
56. Tveit A, Seljeflot I, Grundvold I, Abdelnoor M, Arnesen H, Smith P. Candesartan, NT-proBNP and recurrence of atrial fibrillation after electrical cardioversion. Int J Cardiol 2009;131:234-9.
57. Yamada T, Murakami Y, Okada T, Yoshida N, Toyama J, Yoshida Y, et al. Plasma brain natriuretic peptide level after hybrid therapy with pulmonary vein isolation and antiarrhythmic drugs for atrial fibrillation. Int Heart J 2008;49:143-51.
58. Ahlsson A, Linde P, Rask P, Englund A. Atrial function after epicardial microwave ablation in patients with atrial fibrillation. Scand Cardiovasc J 2008;42:192-201.
59. Magioncalda A, Sartini M, Costaguta C, Castellaneta M, Schenone E, Tognoni E, et al. [The utility of assaying the N-terminal of brain natriuretic peptide precursor (NT pro-BNP) to predict the clinical outcome in patients with supraventricular tachyarrhythmias observed and treated in the emergency room.] Recenti Prog Med 2008;99:141-5.
60. Kawanishi Y, Ito T, Suwa M, Terasaki F, Futai R, Kitaura Y. Effect of left ventricular dyssynchrony on plasma B-type natriuretic peptide levels in patients with long-term right ventricular apical pacing. Int Heart J 2008;49:165-73.
61. Koch A, Zink S, Dittrich S. Plasma levels of B-type natriuretic peptide in children and adolescents with high degree atrioventricular block. Int J Cardiol 2009;134:429-30.
62. Ogawa T, Veinot JP, Kuroski de Bold ML, Georgalis T, de Bold AJ. Angiotensin II receptor antagonism reverts the selective cardiac BNP upregulation and secretion observed in myocarditis. Am J Physiol Heart Circ Physiol 2008;294:H2596-603.
63. Grabowski M, Karpiń ski G, J Filipiak K, Rdzanek A, Pietrasik A, Wretowski D, et al. Diagnostic value of BNP in suspected perimyocarditis - a preliminary report. Kardiol Pol 2004;61:451-8.
64. Kahveci G, Bayrak F, Mutlu B, Bitigen A, Karaahmet T, Sonmez K, et al. Prognostic value of N-terminal pro-B-type natriuretic peptide in patients with active infective endocarditis. Am J Cardiol 2007;99:1429-33.
65. Bayram E, Kocatürk H, Yücel O, Atalay C, Colak MC, Atesal S. The role of adrenomedullin and brain natriuretic peptide levels in acute rheumatic fever in adults. Anadolu Kardiyol Derg 2008;8:188-91.
66. Zhang QY, Du JB, Chen YH, Li WZ. [Change in plasma N-terminal pro-brain natriuretic peptide in children with Kawasaki disease and its value in clinical practice.] Zhonghua Er Ke Za Zhi 2006;44:886-90.
67. Leya FS, Arab D, Joyal D, Shioura KM, Lewis BE, Steen LH, et al. The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. J Am Coll Cardiol 2005;45:1900-2.
68. Babuin L, Alegria JR, Oh JK, Nishimura RA, Jaffe AS. Brain natriuretic peptide levels in constrictive pericarditis and restrictive cardiomyopathy. J Am Coll Cardiol 2006;47:1489-91.
69. Pfister R, Diedrichs H, Larbig R, Erdmann E, Schneider CA. NTpro-BNP for differential diagnosis in patients with syncope. Int J Cardiol 2009;133:51-4.
70. Usui Y, Tomiyama H, Hashimoto H, Takata Y, Inoue Y, Asano K, et al. Plasma B-type natriuretic peptide level is associated with left ventricular hypertrophy among obstructive sleep apnoea patients. J Hypertens 2008;26:117-23.
71. Ybarra J, Planas F, Pou JM. Aminoterminal pro-brain natriuretic peptide (NT-proBNP) and sleep-disordered breathing in morbidly obese females: a cross-sectional study. Diab Vasc Dis Res 2008;5:19-24.
72. Seki S, Tsurusaki T, Kasai T, Taniguchi I, Mochizuki S, Yoshimura M. Clinical significance of B-type natriuretic Peptide in the assessment of untreated hypertension. Circ J 2008;72:770-7.
73. Sbarouni E, Georgiadou P, Marathias A, Geroulanos S, Kremastinos DT. D-dimer and BNP levels in acute aortic dissection. Int J Cardiol 2007;122:170-2.
74. Czernik C, Lemmer J, Metze B, Koehne PS, Mueller C, Obladen M. B-type natriuretic peptide to predict ductus intervention in infants < 28 weeks. Pediatr Res 2008;64:286-90.
75. Farombi-Oghuvbu I, Matthews T, Mayne PD, Guerin H, Corcoran JD. N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2008;93:F257-60.
76. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440-5.
77. Nikolaou NI, Goritsas C, Dede M, Paissios NP, Papavasileiou M, Rombola AT, et al. Brain natriuretic peptide increases in septic patients without severe sepsis or shock. Eur J Intern Med 2007;18:535-41.
78. Nakamura T, Suzuki T, Kawagoe Y, Koide H. Polymyxin Bimmobilized fiber hemoperfusion attenuates increased plasma atrial natriuretic peptide and brain natriuretic Peptide levels in patients with septic shock. ASAIO J 2008;54:210-3.
79. Christ-Crain M, Breidthardt T, Stolz D, Zobrist K, Bingisser R, Miedinger D, et al. Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. J Intern Med 2008;264:166-76.
80. Kandil E, Burack J, Sawas A, Bibawy H, Schwartzman A, Zenilman ME, et al. B-type natriuretic peptide: a biomarker for the diagnosis and risk stratification of patients with septic shock. Arch Surg 2008;143:242-6.
81. Varpula M, Pulkki K, Karlsson S, Ruokonen E, Pettilä V; FINNSEPSIS Study Group. Predictive value of N-terminal probrain natriuretic peptide in severe sepsis and septic shock. Crit Care Med 2007;35:1277-83.
82. Naganuma T, Sugimura K, Wada S, Yasumoto R, Sugimura T, Masuda C, et al. The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol 2002;22:437-44.
83. Goei D, Schouten O, Boersma E, Welten GM, Dunkelgrun M, Lindemans J, et al. Influence of renal function on the usefulness of N-terminal pro-B-type natriuretic peptide as a prognostic cardiac risk marker in patients undergoing noncardiac vascular surgery. Am J Cardiol 2008;101:122-6.
84. Tagore R, Ling LH, Yang H, Daw HY, Chan YH, Sethi SK. Natriuretic peptides in chronic kidney disease. Clin J Am Soc Nephrol 2008;3:1644-51.
85. Biasioli S, Zamperetti M, Borin D, Guidi G, De Fanti E, Schiavon R. Significance of plasma B-type natriuretic peptide in hemodialysis patients: blood sample timing and comorbidity burden. ASAIO J 2007;53:587-91.
86. Winkler K, Wanner C, Drechsler C, Lilienthal J, März W, Krane V; for the German Diabetes and Dialysis Study Investigators. Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. Eur Heart J 2008 Jul 9. [Epubahead of print].
87. Yildiz R, Yildirim B, Karincaoglu M, Harputluoglu M, Hilmioglu F. Brain natriuretic peptide and severity of disease in nonalcoholic cirrhotic patients. J Gastroenterol Hepatol 2005;20:1115-20.
88. Henriksen JH, G∅tze JP, Fuglsang S, Christensen E, Bendtsen F, M∅ller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003;52:1511-7.
89. Januzzi JL, Morss A, Tung R, Pino R, Fifer MA, Thompson BT, et al. Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: a prospective cohort study. Crit Care 2006;10:R37.
90. Levitt JE, Vinayak AG, Gehlbach BK, Pohlman A, Van Cleve W, Hall JB, et al. Diagnostic utility of B-type natriuretic peptide in critically ill patients with pulmonary edema: a prospective cohort study. Crit Care 2008;12:R3.
91. Kia M, Cooley A, Rimmer G, MacDonald T, Barber K, Manion P, et al. The efficacy of B-type natriuretic peptide for early identification of blood loss in traumatic injury. Am J Surg 2006;191:353-7.
92. Tobian AA, Sokoll LJ, Tisch DJ, Ness PM, Shan H. N-terminal pro-brain natriuretic peptide is a useful diagnostic marker for transfusion-associated circulatory overload. Transfusion 2008;48:1143-50.
93. Meyer B, Huelsmann M, Wexberg P, Delle Karth G, Berger R, Moertl D, et al. N-terminal pro-B-type natriuretic peptide is an independent predictor of outcome in an unselected cohort of critically ill patients. Crit Care Med 2007;35:2268-73.
94. Schultz M, Faber J, Kistorp C, Jarl∅v A, Pedersen F, Wiinberg N, et al. N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states. Clin Endocrinol (Oxf) 2004;60:54-9.
95. Wei T, Zeng C, Tian Y, Chen Q, Wang L. B-type natriuretic peptide in patients with clinical hyperthyroidism. J Endocrinol Invest 2005;28:8-11.
96. Ozmen B, Ozmen D, Parildar Z, Mutaf I, Bayindir O. Serum Nterminal-pro-B-type natriuretic peptide (NT-pro-BNP) levels in hyperthyroidism and hypothyroidism. Endocr Res 2007;32:1-8.
97. Anne M, Juha K, Timo M, Mikko T, Olli V, Kyösti S, et al. Neurohormonal activation in ischemic stroke: effects of acute phase disturbances on long-term mortality. Curr Neurovasc Res 2007;4:170-5.
98. Giannakoulas G, Hatzitolios A, Karvounis H, Koliakos G, Charitandi A, Dimitroulas T, et al. N-terminal pro-brain natriuretic peptide levels are elevated in patients with acute ischemic stroke. Angiology 2005;56:723-30.
99. Nakagawa K, Yamaguchi T, Seida M, Yamada S, Imae S, Tanaka Y, et al. Plasma concentrations of brain natriuretic peptide in patients with acute ischemic stroke. Cerebrovasc Dis 2005;19:157-64.
100. Di Angelantonio E, De Castro S, Toni D, Sacchetti ML, Biraschi F, Prencipe M, et al. Determinants of plasma levels of brain natriuretic peptide after acute ischemic stroke or TIA. J Neurol Sci 2007;260:139-42.
101. Montaner J, Perea-Gainza M, Delgado P, Ribó M, Chacón P, Rosell A, et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 2008;39:2280-7.
102. Anne M, Juha K, Timo M, Mikko T, Olli V, Kyösti S, et al. Neurohormonal activation in ischemic stroke: effects of acute phase disturbances on long-term mortality. Curr Neurovasc Res 2007;4:170-5.
103. Berendes E, Walter M, Cullen P, Prien T, Van Aken H, Horsthemke J, et al. Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage. Lancet 1997;349: 245-9.
104. Lu DC, Binder DK, Chien B, Maisel A, Manley GT. Cerebral salt wasting and elevated brain natriuretic peptide levels after traumatic brain injury: 2 case reports. Surg Neurol 2008;69:226-9.
105. Stewart D, Waxman K, Brown CA, Schuster R, Schuster L, Hvingelby EM, et al. B-type natriuretic peptide levels may be elevated in the critically injured trauma patient without congestive heart failure. J Trauma 2007;63:747-50.
106. Tung PP, Olmsted E, Kopelnik A, Banki NM, Drew BJ, Ko N, et al. Plasma B-type natriuretic peptide levels are associated with early cardiac dysfunction after subarachnoid hemorrhage. Stroke 2005;36:1567-9.
107. Espiner EA, Leikis R, Ferch RD, MacFarlane MR, Bonkowski JA, Frampton CM, et al. The neuro-cardio-endocrine response to acute subarachnoid haemorrhage. Clin Endocrinol (Oxf) 2002;56:629-35.
108. Kirchhoff C, Stegmaier J, Bogner V, Buhmann S, Mussack T, Kreimeier U, et al. Intrathecal and systemic concentration of NT-proBNP in patients with severe traumatic brain injury. J Neurotrauma 2006;23:943-9.
109. Yarlagadda S, Rajendran P, Miss JC, Banki NM, Kopelnik A, Wu AH, et al. Cardiovascular predictors of in-patient mortality after subarachnoid hemorrhage. Neurocrit Care 2006;5:102-7.
110. Rauchenzauner M, Haberlandt E, Foerster S, Ulmer H, Laimer M, Ebenbichler CF, et al. Brain-type natriuretic peptide secretion following febrile and afebrile seizures - a new marker in childhood epilepsy? Epilepsia 2007;48:101-6.
111. Obi T, Takatsu M, Konishi T, Mizoguchi K, Nishimura Y. Secretion of natriuretic peptides caused by an epileptic attack. Acta Neurol Scand 2002;106:225-8.
112. Davutoglu V, Gunay N, Kocoglu H, Gunay NE, Yildirim C, Cavdar M, et al. Serum levels of NT-ProBNP as an early cardiac marker of carbon monoxide poisoning. Inhal Toxicol 2006;18:155-8.